Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller
« Previous
123456789101112
Next »

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Feb 1, 2012
By: Jim Miller

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

Troublesome Signs for Bio/Pharmaceutical R&D

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future
Jan 12, 2012
By: Jim Miller

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Jan 2, 2012
By: Jim Miller

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

Troublesome Signs for Bio/Pharmaceutical R&D

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.
Dec 2, 2011
By: Jim Miller

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

Preparing for the Last War

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
Nov 9, 2011
By: Jim Miller

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU Debt Crisis and CMOs

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
Oct 5, 2011
By: Jim Miller

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

Preparing for the Last War

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
Oct 2, 2011
By: Jim Miller

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU Debt Crisis and CMOs

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
Sep 2, 2011
By: Jim Miller

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

Healthy Outlook for Pharma Services

Respondents to the 2011 PharmSource-Pharmaceutical Technology Outsourcing Survey paint a positive picture, but concerns linger under the surface. This article is part of a special issue on Outsourcing.
Aug 1, 2011
By: Jim Miller

Respondents to the 2011 PharmSource-Pharmaceutical Technology Outsourcing Survey paint a positive picture, but concerns linger under the surface. This article is part of a special issue on Outsourcing.

« Previous
123456789101112
Next »

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here